Vilanterol (trifenatate) Catalog No.:M9740-2 neohesperidin (50 mg/kg) significantly decreases

neohesperidin (50 mg/kg) significantly decreases the volume of gastric secretion and gastric acid output

Metformin decreases hepatic glucose production and increases skeletal myocyte glucose uptake

UNC0379 is active in multiple biochemical assays

T-5224 has been investigated in phase II human clinical trials

Vilanterol (trifenatate) Catalog No.:M9740-2 neohesperidin (50 mg/kg) significantly decreasesVilanterol, also known as GW 642444, is a long acting beta 2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Product information CAS Number: 503070 58 4 Molecular Weight: 774. 77 Formula: C44H49Cl2NO7 Chemical Name: 4 [(1R) 2 [(6 {2 [(2,6 dichlorophenyl)methoxy]ethoxy}hexyl)amino] 1 hydroxyethyl] 2